- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears Shimadzu hybrid CT
Shimadzu Medical Systems has highhopes for its new SCT-4800 line of CT scanners. The vendor hasalready sold 10 systems in the U.S. since the Food and Drug Administrationcleared the line in July. Shimadzu is targeting sales of 40 systemsin the U.S. and
Shimadzu Medical Systems has highhopes for its new SCT-4800 line of CT scanners. The vendor hasalready sold 10 systems in the U.S. since the Food and Drug Administrationcleared the line in July. Shimadzu is targeting sales of 40 systemsin the U.S. and 400 worldwide by March 1995, according to DonKarle, marketing manager of CT and MRI for the Torrance, CA-basedvendor.
Shimadzu unveiled the SCT-4800 series at last year's RadiologicalSociety of North America conference (SCAN 11/17/94). The seriesincludes SCT-4800TF, a higher end scanner, and SCT-4800TE. Bothsystems are non-spiral scanners and list below $500,000.
The 4800 line is unique in that its x-ray generator can powerboth the CT scanner and a radiographic room. This is an addedplus in developing countries such as those in southeast Asia,according to Karle. The scanners are marketed outside the U.S.as Intellect FXT and Intellect EXT.
In other Shimadzu news, MRI director Mark Silverman has leftthe company. Silverman was brought on in an attempt to jump-startShimadzu's MRI effort (SCAN 7/28/93). Shimadzu decided to scaleback its MRI sales program earlier this year, and Silverman waslet go as part of that restructuring (SCAN 7/13/94). Karle willassume Silverman's responsibilities.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
